These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 29412124)

  • 21. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Rajasekeran H; Cherney DZ; Lovshin JA
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
    Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
    Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
    Kim YJ; Hwang SD; Lim S
    Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 26. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Krogh J; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD012106. PubMed ID: 27101360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
    Storgaard H; Gluud LL; Christensen M; Knop FK; Vilsbøll T
    BMJ Open; 2014; 4(8):e005378. PubMed ID: 25232561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
    Permana H; Audi Yanto T; Ivan Hariyanto T
    Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
    Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions.
    Pantelidis P; Kalliakmanis A; Mitas C; Sideris M; Grassos C; Pittaras A; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):86-93. PubMed ID: 29412123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
    Dicembrini I; Tomberli B; Nreu B; Baldereschi GI; Fanelli F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2019 Jul; 153():138-144. PubMed ID: 31150722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
    Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
    Imprialos KP; Stavropoulos K; Stavropoulos N; Patoulias D; Petidis K; Grassos C; Dimitriadis K; Tsioufis C
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):104-113. PubMed ID: 29412121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
    Maccari R; Ottanà R
    J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis.
    Duo Y; Gao J; Yuan T; Zhao W
    J Diabetes; 2023 Jan; 15(1):58-70. PubMed ID: 36610036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.